SAB Biotherapeutics, Inc. SEC filings SABS

SAB Biotherapeutics, Inc. has 433 filings in SEC EDGAR's recent list, going back to Dec 7, 2020. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.

SAB Biotherapeutics, Inc. SEC filings
Form Description Filed Period
10-K Annual report Mar 9, 2026 Dec 31, 2025
10-K Annual report Mar 31, 2025 Dec 31, 2024
10-K Annual report Mar 29, 2024 Dec 31, 2023
10-K/A Amended annual report Apr 28, 2023 Dec 31, 2021
10-K/A Amended annual report Apr 28, 2023 Dec 31, 2022
10-K Annual report Apr 14, 2023 Dec 31, 2022
10-K Annual report Mar 29, 2022 Dec 31, 2021
10-K Annual report Apr 2, 2021 Dec 31, 2020

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
SABS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Miami Beach, FL
SEC filer status
, Emerging growth company
SEC CIK
1833214
Former names
Big Cypress Acquisition Corp. (until Oct 22, 2021)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.